<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435419</url>
  </required_header>
  <id_info>
    <org_study_id>P08020-AFG</org_study_id>
    <nct_id>NCT03435419</nct_id>
  </id_info>
  <brief_title>Evaluation of Point-of-care Tests for the Diagnosis of Cutaneous Leishmaniasis in Afghanistan</brief_title>
  <acronym>CLeishPOCAFG</acronym>
  <official_title>Point of Care Tests for Cutaneous Leishmaniasis: Prospective Evaluation of LoopampTM and CL DetectTM Rapid Test for Cutaneous Leishmaniasis Diagnosis in Afghanistan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      New point-of-care (POC) tests are needed and assessing the performance of these tests for
      cutaneous leishmaniasis (CL) in Afghanistan may help increasing the number of CL patients
      with access to accurate diagnosis, and enable prompt treatment. Simpler tests could improve
      treatment access and benefit patients and communities, by reducing the risk of sequelae and
      the risk of disease transmission. CLeishPOCAFG aims to advance the diagnosis of CL by using
      more accurate and field-amenable methods.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators enrolled 274 CL suspects in the study to determine the diagnostic
      performance of LoopampTM Leishmania Detection Kit and CL DetectTM Rapid Test for CL diagnosis
      in Afghanistan. The study was conducted at the National Malaria &amp; Leishmaniasis Control
      Program (NMLCP) Leishmaniasis Clinic in Kabul, Afghanistan.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2016</start_date>
  <completion_date type="Actual">July 18, 2016</completion_date>
  <primary_completion_date type="Actual">June 22, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance of CL Detect RDT and Loopamp Leishmania Detection Kit</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Sensitivity and Specificity of the two diagnostic tests</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">274</enrollment>
  <condition>Cutaneous Leishmaniases</condition>
  <arm_group>
    <arm_group_label>CL suspects</arm_group_label>
    <description>Individuals with suggestive signs of cutaneous leishmaniasis presenting themselves at the National Malaria &amp; Leishmaniasis Control Program (NMLCP) Leishmaniasis clinic in Kabul, Afghanistan.
These will be tested by diagnostic tests under evaluation:
i) LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection ii) CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection And their performance compared against a reference combining microscopy and PCR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>LoopampTM Leishmania Detection Kit</intervention_name>
    <description>LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection</description>
    <arm_group_label>CL suspects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CL DetectTM Rapid Test</intervention_name>
    <description>CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection</description>
    <arm_group_label>CL suspects</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Skin samples from cutaneous lesions obtained with a dental broach. Sample stored in lysis
      buffer accompanying the RDT kit. DNA extracted using commercial kit.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        CL suspects attending the National Malaria &amp; Leishmaniasis Control Program (NMLCP)
        Leishmaniasis clinic in Kabul will be invited to enroll the study. Samples from prospective
        participants will be subjected to standard diagnostic procedure (Giemsa's smear
        microscopy), as well as PCR (confirmation test to be performed at AMC, The Netherlands) and
        the two new tests under evaluation, in order to determine the diagnostic accuracy of LAMP
        and CL Detect.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical signs compatible with cutaneous leishmaniasis

          -  Age ≥ than two years old.

          -  Informed consent obtained and documented.

          -  Clinical samples can be obtained.

        Exclusion Criteria:

          -  Age less than two years old.

          -  Failure to obtain and document informed consent.

          -  Cutaneous leishmaniasis suspects from whom, for any reason, the required clinical
             samples needed for the study cannot be obtained.

          -  Patients already receiving CL treatment at the time of enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martijn Vink, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>HealthNet TPO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Israel Cruz, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Foundation for Innovative New Diagnostics</affiliation>
  </overall_official>
  <link>
    <url>http://apps.who.int/iris/bitstream/10665/44412/1/WHO_TRS_949_eng.pdf</url>
    <description>WHO. Control of the Leishmaniases</description>
  </link>
  <reference>
    <citation>Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M; WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671. doi: 10.1371/journal.pone.0035671. Epub 2012 May 31.</citation>
    <PMID>22693548</PMID>
  </reference>
  <reference>
    <citation>Eroglu F, Uzun S, Koltas IS. Comparison of clinical samples and methods in chronic cutaneous leishmaniasis. Am J Trop Med Hyg. 2014 Nov;91(5):895-900. doi: 10.4269/ajtmh.13-0582. Epub 2014 Sep 15.</citation>
    <PMID>25223940</PMID>
  </reference>
  <reference>
    <citation>Marfurt J, Nasereddin A, Niederwieser I, Jaffe CL, Beck HP, Felger I. Identification and differentiation of Leishmania species in clinical samples by PCR amplification of the miniexon sequence and subsequent restriction fragment length polymorphism analysis. J Clin Microbiol. 2003 Jul;41(7):3147-53.</citation>
    <PMID>12843055</PMID>
  </reference>
  <reference>
    <citation>Masmoudi A, Hariz W, Marrekchi S, Amouri M, Turki H. Old World cutaneous leishmaniasis: diagnosis and treatment. J Dermatol Case Rep. 2013 Jun 30;7(2):31-41. doi: 10.3315/jdcr.2013.1135. Print 2013 Jun 30.</citation>
    <PMID>23858338</PMID>
  </reference>
  <reference>
    <citation>Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, Hase T. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000 Jun 15;28(12):E63.</citation>
    <PMID>10871386</PMID>
  </reference>
  <reference>
    <citation>Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis. 2007 Sep;7(9):581-96. Review.</citation>
    <PMID>17714672</PMID>
  </reference>
  <reference>
    <citation>De Silva G, Somaratne V, Senaratne S, Vipuladasa M, Wickremasinghe R, Wickremasinghe R, Ranasinghe S. Efficacy of a new rapid diagnostic test kit to diagnose Sri Lankan cutaneous leishmaniasis caused by Leishmania donovani. PLoS One. 2017 Nov 14;12(11):e0187024. doi: 10.1371/journal.pone.0187024. eCollection 2017.</citation>
    <PMID>29135995</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2018</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cutaneous leishmaniasis</keyword>
  <keyword>RDT</keyword>
  <keyword>LAMP</keyword>
  <keyword>PCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

